388
Participants
Start Date
April 11, 2022
Primary Completion Date
February 17, 2023
Study Completion Date
February 17, 2023
Influenza Hemagglutinin mRNA vaccine
Pharmaceutical form:Solution for injection-Route of administration:IM injection
Quadrivalent Recombinant Influenza Vaccine
Pharmaceutical form:Solution for injection-Route of administration:IM injection
Velocity Clinical Research Vestal Site Number : 8400033, Vestal
Coastal Carolina Research Center - N Charleston Site Number : 8400008, North Charleston
Meridian Clinical Research, LLC Site Number : 8400016, Savannah
Research Centers of America Site Number : 8400003, Hollywood
AMR Coral Gables/Miami, Formerly Clinical Research of South Florida, an AMR company (Clinic) Site Number : 8400004, Coral Gables
AMR Knoxville Site Number : 8400027, Knoxville
AMR Lexington Site Number : 8400014, Lexington
AES Peoria Site Number : 8400017, Peoria
AMR El Dorado Site Number : 8400009, El Dorado
AMR - Newton Site Number : 8400005, Newton
AMR Wichita West Site Number : 8400030, Wichita
Quality Clinical Research Site Number : 8400018, Omaha
Velocity Clinical Research, Omaha Site Number : 8400007, Omaha
Benchmark Research Site Number : 8400010, Metairie
Clinical Trials of Texas, Inc. Site Number : 8400012, San Antonio
Elligo Health Research, Inc. Site Number : 8400035, Austin
Benchmark Research - Austin Site Number : 8400006, Austin
AES Austin Site Number : 8400021, Austin
Peninsula Research Associates Site Number : 8400013, Rolling Hills Estates
Optimal Research Site Number : 8400026, San Diego
Sanofi Pasteur, a Sanofi Company
INDUSTRY